Touchstone Innovations throws another £3m at promising Pulmocide

Josh White Sharecast | 20 Mar, 2017 16:00 - Updated: 16:00 | | |

money pounds cash

Touchstone Innovations

314.50

17:17 28/04/17
4.01%
12.13
  • 10,293.72
  • -0.58%-60.16
  • Max: 10,366.92
  • Min: 10,293.72
  • Volume: 0
  • MM 200 : n/a
17:20 28/04/17

Touchstone Innovations announced on Monday that it participated in a £25m Series B funding round in Pulmocide, committing £3m to the round alongside new investors SR One and Longwood Fund, plus existing investors SV Life Sciences, F-Prime Capital, and Johnson & Johnson Innovation.

The AIM-traded company described Pulmocide as a privately-held drug development company located in London, which was developing novel small molecule inhaled medicines for the treatment of life threatening respiratory infections caused by respiratory syncytial virus (RSV) and Aspergillus.

It said the new funding would enable Pulmocide to advance its assets through early clinical development.

Pulmocide was reportedly on track to deliver proof of concept data in RSV using its highly potent inhaled RSV antiviral agent ‘PC786’ in human RSV challenge and in infants hospitalised with bronchiolitis due to RSV infection.

Pulmocide would also be progressing its ‘PC945’, described as a potent azole antifungal for the treatment of pulmonary Aspergillosis, including fungal asthma, pulmonary Aspergilloma, Aspergillus infections in lung transplant recipients and patients with cystic fibrosis.

“We continue to support this strong entrepreneurial management team to progress the company's two novel compounds through early clinical development; another step closer to a treatment for patients with life-threatening lung infections,” said Touchstone’s director of healthcare ventures Maina Bhaman.

“Pulmocide is yet another example of a portfolio company that has been able to attract a powerful group of investors and we would like to welcome SR One and Longwood to the syndicate.”

As at 31 July, Touchstone Innovations had a 24.1% interest in the issued share capital of Pulmocide.

Following the new investment, it will hold an 18.5% stake in the issued share capital of the company.

More news

28 Apr S&P reaffirms AA rating on UK, outlook clouded by Brexit

Standard&Poor's reaffirmed its rating on the United Kingdom's long-term sovereign debt but warned of the potential impact on the economy from the uncertainty around the Brexit negotiations and their eventual outcome.

28 Apr FX round-up: Sterling nonchalant after UK Q1 growth disappoints

Sterling made steady gains on most key cross on Friday, appearing nonchalant in its reaction to disappointing UK economic growth data out mid-morning.

28 Apr Europe close: Weak US, UK GDP weigh on shareson the continent

European stocks ended the day on a mixed note after weak readings on UK and US GDP dragged many indices into the red at the end of the month.

28 Apr Laird off to solid start, but second half remains key

Electronic component maker Laird reported strong sales growth in the first quarter of 2017 after a difficult year.

28 Apr General Motors truck and SUV sales drive record earnings

Growth at General Motors accelerated past analyst forecasts with a record first-quarter set of earnings.

28 Apr RBS and Lloyds Bank customers hit by online glitch on payday

Royal Bank of Scotland and Lloyds Banking Group customers were prevented from accessing money in their accounts due to a technical glitch ahead of the bank holiday weekend.

28 Apr Kennedy Wilson confirms quarterly dividend, new office leases

Kennedy Wilson Europe Real Estate announced it will pay an interim quarterly dividend of 12.0p per share, while also reporting strong leasing momentum across key investments in Greater London and Dublin.

28 Apr Time spins backwards on decision not to sell business

Time Inc stock reversed recent gains after the board decided not to sell the publishing business as it was being "reinvigorated" under a new strategy.

28 Apr Morgan Stanley downgrades Berendsen on competition concerns

Berendsen not only needs to invest in property, plant and equipment but is facing increasing competition in the UK, warned Morgan Stanley as it downgraded the stock on Friday.

28 Apr UK mortgages and consumer credit card borrowing both decline - BBA

Mortgage approvals and consumer credit card lending both fell in March according to fresh data from the banking industry, providing the reason for the fall in house prices announced elsewhere on Friday.